An article on positive 2-year preclinical data on Xeltis’ pulmonary valve performance will be published in the peer-reviewed journal EuroIntervention. The study results showed favorable and durable hemodynamic performance up to 2-years after implantation, without conduit narrowing/obstruction or severe regurgitation. The article is currently available online.
“These results are very encouraging on the longer-term potential of a restorative approach in heart valve therapy,” commented Xeltis’ CTO Martijn Cox. “The pulmonary valve is our most advanced product and this, combined with the growing body of evidence on our aortic valve, collectively support the potential of ETR for hundreds of thousands of patients requiring heart valve replacement,” he concluded.
EuroIntervention journal’s aim is to create a community of high quality research and education in the field of percutaneous and surgical cardiovascular interventions. It is the official publication of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and it is endorsed by The European Society of Cardiology (ESC). The September edition also included a feature on how ETR may help overcome the limitations of heart valve options currently available.
